bioihbjkbjnl/mcl2 huggingface dataset:
The Role of Secretin on the Energy Homeostasis
Condition: Obesity; Metabolic Disease; Diabetes; Adiposity
MeSH terms: Metabolic Diseases
Study type: Interventional

Summary: 
      As of last year, new insight into the function of secretin was brought about as rodent
      studies showed secretin to possess potential body weight-regulating effects. In these
      studies, secretin was shown to increase non-shivering thermogenesis in brown adipose tissue
      (BAT), decrease meal size and promote meal discontinuation. The mechanisms behind these
      regulatory effect of secretin on energy homeostasis are unclear,
    

Detailed description: 
      Secretin was - as the first hormone - identified in 19021, but was not isolated until the
      1960s. Secretin is produced in and secreted form small intestinal S cells. In the 1970s, the
      primary endocrine effects of secretin were unequivocally confirmed, namely potentiation of
      bicarbonate and pepsin secretion from the pancreas as well as stimulation of bile production
      in the liver. In the 1990s, the biosynthesis of secretin was delineated and its receptor was
      discovered. In the 2000s the pancreatic regulation of intestinal pH was shown to be
      secretin-mediated. As of last year, new insight into the function of secretin was brought
      about as rodent studies showed secretin to possess potential body weight-regulating effects.
      In these studies, secretin was shown to increase non-shivering thermogenesis in brown adipose
      tissue (BAT), decrease meal size and promote meal discontinuation.

      The primary aim of this study is to evaluate the effect of a 5-hour intravenous infusion with
      the naturally occurring hormone secretin on ad libitum food intake (primary endpoint)
      compared to a double-blinded placebo (isotonic saline) infusion in 25 healthy young males.
    

Intervention name(s): Secretin; Placebo
Intervention type(s): Drug; Other
Intervention description(s): Native hormone; Saline
Intervention MeSH terms: Secretin
Allocation: Randomized
Intervention model: Crossover Assignment
Intervention model description: randomised, double-blinded, placebo-controlled, cross-over study
Masking: Triple (Participant, Care Provider, Investigator)
Primary purpose: Basic Science
Diet and Exercise for Underserved Women
Condition: Obesity
Study type: Interventional

Summary: 
      The purpose is to determine if a culturally tailored diet and exercise intervention of 16
      weekly sessions with 8 weeks of followup phone support is effective in reducing waist
      circumference, weight, and related diet and exercise behaviors among women from underserved
      communities.
    

Detailed description: 
      Overweight and obesity disproportionately impact economically disadvantaged and minority
      women. Overweight and obese women ages 25 to 50 are recruited from Census tracts with 25% or
      more residents living below poverty-level income. A skills-based intervention was designed
      with input from women in these communities gathered via focus groups and from a community
      advisory board. The intervention activities and strategies take into consideration the social
      and economic challenges of women with limited income, competing demands on their time and
      cultural beliefs about food preferences and body image.
    

Intervention name(s): Behavioral and support intervention; Wait-listed control group
Intervention type(s): Behavioral; Behavioral
Intervention description(s): Individual counseling session with diet and exercise recommendations, 16 weekly group sessions, 8 weeks of followup phone support; Controls receive the same individual counseling session as intervention group; receive mailed health information; are offered group sessions after last post-measure
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Prevention
Keywords: behavioral; diet; exercise
Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects
Condition: Diabetes; Diabetes Mellitus, Type 2; Healthy
MeSH terms: Diabetes Mellitus; Diabetes Mellitus, Type 2
Study type: Interventional
Phase: Phase 1

Summary: 
      This trial is conducted in Europe. The aim of the trial is to evaluate the optimal dosing
      conditions for semaglutide (a long acting GLP-1 analogue) in healthy male subjects.
    


Intervention name(s): semaglutide; semaglutide; semaglutide; semaglutide; semaglutide; semaglutide; semaglutide; semaglutide
Intervention type(s): Drug; Drug; Drug; Drug; Drug; Drug; Drug; Drug
Intervention description(s): Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 120 mins, no food or liquid is allowed.; Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 60 mins, no food or liquid is allowed.; Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 30 mins, no food or liquid is allowed.; Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 15 mins, no food or liquid is allowed.; Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 120 mins, no food or liquid is allowed.; Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 60 mins, no food or liquid is allowed.; Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 30 mins, no food or liquid is allowed.; Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 15 mins, no food or liquid is allowed.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Using Text Messages to Boost COVID-19 Vaccine Booking Rate
Condition: Vaccination Hesitancy; COVID-19
MeSH terms: COVID-19
Study type: Interventional

Summary: 
      This study is a nationwide randomised controlled trial (RCT) to test the impact of
      behavioural science-informed text messages notifying patients of their eligibility for the
      COVID-19 vaccine on vaccination rates.
    


Intervention name(s): Behavioural science-informed text messages; Control
Intervention type(s): Behavioral; Behavioral
Intervention description(s): Behaviourally-informed content in vaccination eligibility reminder text messages; Control vaccination eligibility reminder text message
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary purpose: Prevention
Neural Correlates of Stress Hormones
Condition: Borderline Personality Disorder; PTSD
MeSH terms: Personality Disorders; Borderline Personality Disorder
Study type: Interventional

Summary: 
      To investigate which neuronal correlates underlie cortisol-induced enhancement of memory
      retrieval in PTSD and BPD.
    

Detailed description: 
      The investigators have recently shown that hydrocortisone enhances rather than impairs memory
      retrieval in patients with posttraumatic stress disorder (PTSD) and borderline personality
      disorder (BPD). In contrast, in healthy participants memory retrieval was impaired after
      hydrocortisone compared to placebo.

      The proposed studies aim to further investigate these findings and to understand the
      underlying neuronal correlates. Thus, the mechanisms of enhanced memory retrieval after
      hydrocortisone in patients with BPD and PTSD will be investigated by fMRI.

      In a placebo-controlled study, the effects of 10mg hydrocortisone on brain activity, in
      particular the hippocampus, will be investigated in patients with PTSD and BPD and will be
      compared with those in healthy control participants. During the fMRI session, a declarative
      memory task (retrieval of a previous learned word list) and an autobiographical memory test
      will be performed. Effects of hydrocortisone on resting state brain activity and the neuronal
      correlates of memory retrieval will be analysed.
    

Intervention name(s): Hydrocortisone; Placebo
Intervention type(s): Drug; Drug
Intervention description(s): effects of hydrocortisone on memory while fMRI
Intervention MeSH terms: Hydrocortisone
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Basic Science
Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma
Condition: Endometrial Cancer; Sarcoma
MeSH terms: Sarcoma; Endometrial Neoplasms
Study type: Interventional
Phase: Phase 2

Summary: 
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die.

      PURPOSE: Phase II trial to study the effectiveness of perifosine in treating patients who
      have metastatic or locally advanced soft tissue sarcoma.
    

Detailed description: 
      OBJECTIVES:

        -  Determine the efficacy of perifosine, in terms of response rate and duration of
           response, in patients with untreated metastatic or locally advanced soft tissue sarcoma.

        -  Determine the toxicity of this drug in these patients.

        -  Determine the early progression rate in patients treated with this drug.

      OUTLINE: This is a non-randomized, non-blinded, multicenter study.

      Patients receive a loading dose of oral perifosine twice on day 1 and then once daily on days
      2-21 for the first course. For all subsequent courses, patients receive a loading dose of
      oral perifosine once on day 1 and then once daily on days 2-21. Courses repeat every 28 days
      in the absence of disease progression or unacceptable toxicity.

      Patients are followed for 1 month. Patients with stable or responsive disease are followed
      every 3 months thereafter.

      PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study within 12-18
      months.
    

Intervention name(s): perifosine
Intervention type(s): Drug
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: adult alveolar soft-part sarcoma; adult angiosarcoma; adult fibrosarcoma; adult leiomyosarcoma; adult liposarcoma; adult synovial sarcoma; endometrial stromal sarcoma; uterine leiomyosarcoma; adult malignant hemangiopericytoma; stage III adult soft tissue sarcoma; stage III uterine sarcoma; stage IV uterine sarcoma; recurrent adult soft tissue sarcoma; recurrent uterine sarcoma; adult malignant fibrous histiocytoma; adult neurofibrosarcoma; adult rhabdomyosarcoma; stage IV adult soft tissue sarcoma
Effects of Moxaverine and Placebo on Ocular Blood Flow
Condition: Regional Blood Flow; Ocular Physiology; Retina
Study type: Interventional
Phase: Phase 2

Summary: 
      A number of common eye diseases such as retinal artery and vein occlusion, diabetic
      retinopathy, age-related macular degeneration, glaucoma and anterior ischemic optic
      neuropathy are associated with ocular perfusion abnormalities. Although this is well
      recognized there is not much possibility to improve blood flow to the posterior pole of the
      eye in these diseases.

      Since many years, moxaverine is used in the therapy of perfusion abnormalities in the brain,
      the heart and the extremities. This is based on a direct vasodilator effect of the drug, but
      also on the rheological properties of red blood cells. Whether moxaverine affects blood flow
      in the eye is unknown. The present study aims to investigate whether moxaverine may improves
      blood flow in the eye after systemic administration.
    


Intervention name(s): Moxaverine; Moxaverin 150mg; NaCl
Intervention type(s): Drug; Drug; Drug
Intervention description(s): intravenous administration; intravenous administration
Other intervention name(s): Collateral i
Intervention MeSH terms: Moxaverine
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
Condition: Major Depressive Disorder
MeSH terms: Depressive Disorder; Depression; Depressive Disorder, Major
Study type: Interventional
Phase: Phase 3

Summary: 
      To evaluate the long-term efficacy and safety of brexpiprazole as an adjunctive treatment to
      an antidepressant treatment (ADT) for adult patients with Major Depressive Disorder (MDD).
    

Detailed description: 
      The total duration of the study was 32 weeks and the study consisted of Periods A, B, and A+.
      Patients entered the study in Period A and were treated open-label with one of six
      commercially available antidepressant treatments (ADTs) for 8 weeks. Patients who met the
      blinded response criteria at the Week 6 Visit, were deemed early responders and were
      withdrawn from the study. At Week 8, patients with inadequate response to placebo + ADT, as
      per the randomisation criteria, entered Period B and were randomised to received double-blind
      brexpiprazole + ADT or placebo + ADT for 24 weeks. Non-randomised patients continued in
      Period A+ and received placebo + ADT until the end of the study. The primary objective was to
      compare the efficacy and safety of brexpiprazole with placebo. This comparison occurred
      Period B; therefore, the focus is Period B.
    

Intervention name(s): Placebo; Brexpiprazole; ADT
Intervention type(s): Drug; Drug; Drug
Intervention description(s): Once daily, tablets, orally; 1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 1 mg/day; Duloxetine, escitalopram, fluoxetine, paroxetine IR, sertraline, venlafaxine XR; dosing according to label
Intervention MeSH terms: Brexpiprazole
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Stress Management Intervention in Women's Heart Clinic, Heart SMART Program
Condition: Stress
Study type: Interventional

Summary: 
      Will the intervention (Heart SMART program) be feasible in moderate or high stress patients,
      who are referred to the Women's Heart and Preventive Cardiology clinics at Mayo Clinic?
    

Detailed description: 
      The Heart SMART Program is designed to offer a practical and efficacious stress management
      and resiliency intervention. It involves making participants aware of practices to enhance
      present moment awareness and engagement. It teaches learners to train their attention, and
      refine interpretation; utilizing principles of gratitude, compassion, acceptance, higher
      meaning and forgiveness. Participants will choose to use one of two delivery methods (either
      the face to face method or the on-line method) of the Heart SMART program.
    

Intervention name(s): Face to Face Heart SMART Program; On-line Heart SMART Program; Mayo Clinic Guide to Stress Free Living
Intervention type(s): Behavioral; Behavioral; Behavioral
Intervention description(s): The Heart SMART stress management program survey consists of Perceived Stress Scale (PSS), Brief Resilience Scale (BRS), Patient Health Questionnaire (PHQ - 9) and Generalized Anxiety Disorder (GAD - 7), followed by email communication every three weeks.; The Heart SMART stress management program survey consists of PSS (Perceived Stress Scale), BRS (Brief Resilience Scale), PHQ-9 (Patient Health Questionnaire) and GAD-7 (Generalized Anxiety Disorder) taken on-line in twelve, 10 minutes sessions.; All subjects will be provided with a copy of the book entitled Mayo Clinic Guide to Stress Free Living and encouraged to read it over the twelve week study period.
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Supportive Care
A Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations
Condition: Lymphangioma
MeSH terms: Lymphangioma; Lymphatic Abnormalities; Congenital Abnormalities
Study type: Interventional
Phase: Phase 1/Phase 2

Summary: 
      There is an unsatisfied medical need for a first-line treatment of lymphatic malformations
      with a good benefit/risk profile. Based on a patient experience in the institution, the
      investigators plan to verify whether or not the medication sildenafil has a beneficial effect
      on lymphatic malformations. The investigators plan to do this by treating patients with
      lymphatic malformations with the medication sildenafil for a 20 week period. This is an
      investigator initiated study funded by an Innovations in Patient Care grant and a SPARK
      grant.
    

Detailed description: 
      Lymphatic malformations can be challenging to treat. Mainstay interventions including surgery
      and sclerotherapy are invasive and can result in local recurrence and complications. We
      sought to assess the effect of 20 weeks of oral sildenafil on reducing lymphatic malformation
      volume and symptoms in children. Seven children (4 boys, 3 girls; ages 13-85 months) with
      lymphatic malformations were given oral sildenafil for 20 weeks in this open-label study. The
      volume of the lymphatic malformation was calculated blindly using magnetic resonance imaging
      performed before and after 20 weeks of sildenafil. Lymphatic malformations were assessed
      clinically on weeks 4, 12, 20, and 32. Both the physician and parents evaluated the lymphatic
      malformation in comparison with baseline. Sildenafil can reduce lymphatic malformation volume
      and symptoms in some children. ( J Am Acad Dermatol 2014;70:1050-7.)
    

Intervention name(s): Sildenafil
Intervention type(s): Drug
Intervention description(s): Sildenafil oral tablet three times daily
Other intervention name(s): Revatio; Viagra
Intervention MeSH terms: Sildenafil Citrate
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Lymphatic malformation, vascular malformation
Vitamin D Supplementation in Vitamin Deficient Women Undergoing IVF Cycles: Does it Affect the Fertility Outcome?
Condition: Infertility
MeSH terms: Infertility
Study type: Interventional
Phase: Phase 4

Summary: 
      The aim of this study is to evaluate the effect of treatment of vitamin D deficiency (through
      vitamin D supplementation for 8 weeks before the start of In-vitro fertilization (IVF) on the
      success of IVF cycles.
    

Detailed description: 
      The study participants are vitamin D deficient females undergoing (intra-cytoplasmic sperm
      injection (ICSI) trial in the age of 20 to 35 years. Serum vitamin D will be assessed.
      Accordingly, if they are deficient in vitamin D, they will be eligible for the study.400
      vitamin D deficient women will be randomly allocated to either one of two groups. The first
      group will receive vitamin D supplementation in addition to the routine care. The other group
      will receive the routine care only. The study will be conducted in the IVF unit of department
      of Obstetrics and Gynecology, Cairo University.
    

Intervention name(s): Vitamin D
Intervention type(s): Drug
Intervention description(s): Vitamin D supplement will be given. Then, it will be maintained if pregnancy occurred
Other intervention name(s): Calcitriol
Intervention MeSH terms: Vitamin D; Calcitriol
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Botulinum Toxin Injection in Epicardial Fat Pads To Treat Atrial Fibrillation After Cardiac Surgery
Condition: Paroxysmal Atrial Fibrillation; Indications for CABG
MeSH terms: Atrial Fibrillation
Study type: Interventional
Phase: Phase 2

Summary: 
      The aim of this prospective randomized double-blind study was to compare the efficacy and
      safety of Botulinum toxin injection in epicardial fat pads for preventing recurrences (in
      early postoperative period) of atrial tachyarrhythmia in patients with paroxysmal atrial
      fibrillation undergoing coronary artery bypass graft (CABG) surgery.
    


Intervention name(s): botulinum toxin injection; 0.9% normal saline injection; Implantable loop recorder
Intervention type(s): Biological; Biological; Device
Intervention MeSH terms: Botulinum Toxins
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary purpose: Treatment